September 13, 2020
Contact: Shea McCarthy
Phone: (202) 285-3866
It is well documented that patients and people with disabilities who live outside of the United States experience worse health outcomes due to their lack of access to needed treatments. In fact, the National Council on Disability (NCD), an independent government agency, released a report on QALYs recommending policymakers refrain from using QALYs, citing access barriers and delays to cutting edge therapies that lead to worse patient outcomes in countries like the United Kingdom. For the same reasons, the NCD called for the Trump Administration to rescind its Advanced Notice of Proposed Rulemaking that proposed an international pricing index for Medicare, and more recently, issued a statement on August 5, 2020 opposing the President’s most recent actions to import QALYs. They noted in both instances, the policies would discriminate against people with disabilities by referencing countries that make pricing decisions based on QALYs and similar metrics.
Addressing health care costs, including drug prices, is an important and meaningful effort, which should center on improving health outcomes and reducing the out-of-pocket costs of patients and people with disabilities. This policy achieves neither goal, and is in fact, simply dangerous to their health.
For additional information about the NCD report, please visit www.ncd.gov.